Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease

Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease

Abstract Patients with inflammatory bowel disease (IBD) treated with biologic and/or immunosuppressant drugs are at increased risk for opportunistic infections. Seroprevalence studies can confirm the diagnosis of SARS-CoV-2 infections as well as the associated risk factors. This is a descriptive stu...

Full description

Bibliographic Details
Main Authors: M. D. Martin-Arranz, L. García-Ramírez, M. Hernandez-Perez, D. Montero Vega, E. Martín-Arranz, M. Sánchez-Azofra, J. Poza Cordon, J. L. Rueda Garcia, J. Noci Belda, T. Verges Martínez-Meco, P. Blanco San Miguel, C. Suarez Ferrer
Format: Article
Language:English
Published: Nature Portfolio 2023-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-33402-w

Internet

https://doi.org/10.1038/s41598-023-33402-w

Similar Items